Chronic myeloid leukemia in children and adolescents Chronische myeloische Leukämie bei Kindern und Jugendlichen
Suttorp M, Metzler M (2025)
Publication Type: Journal article
Publication year: 2025
Journal
Book Volume: 31
Pages Range: 828-838
Journal Issue: 8
DOI: 10.1007/s00761-025-01771-8
Abstract
Chronic myeloid leukemia (CML) is a myeloproliferative disease with a peak incidence in advanced adulthood. In childhood and adolescence, it is a rare form of leukemia compared to acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). The early manifestation is partly favored by the cooperation of constitutional germline variants with the oncogene BCR::ABL1. The clinical characteristics and treatment of pediatric CML in a growing organism are particular, requiring adaptation of the treatment strategies established for adults. Imatinib, dasatinib, nilotinib, and bosutinib are currently available as approved tyrosine kinase inhibitors (TKIs) for children and adolescents. Treatment with TKIs has also displaced allogeneic stem cell transplantation to subordinate lines of therapy in children. The side effect profile of TKIs in young patients varies to some extent from that in older patients. After maintaining a deep molecular response over several years, some patients can achieve treatment-free remission.
Authors with CRIS profile
Markus Metzler
Professur für Kinder- und Jugendmedizin mit dem Schwerpunkt Pädiatrische Onkologie und Hämatologie
Involved external institutions
Germany (DE)How to cite
APA:
Suttorp, M., & Metzler, M. (2025). Chronic myeloid leukemia in children and adolescents Chronische myeloische Leukämie bei Kindern und Jugendlichen. Die Onkologie, 31(8), 828-838. https://doi.org/10.1007/s00761-025-01771-8
MLA:
Suttorp, Meinolf, and Markus Metzler. "Chronic myeloid leukemia in children and adolescents Chronische myeloische Leukämie bei Kindern und Jugendlichen." Die Onkologie 31.8 (2025): 828-838.
BibTeX: Download